Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Liquid biopsies can accurately identify molecular alterations in patients with colorectal cancer with high concordance with tissue analysis and shorter turnaround times. Circulating tumor (ct) DNA analysis can be used for diagnosing and monitoring tumor evolution in patients with metastatic colorectal cancer who are treated with EGFR inhibitors. In this article, we reported three clinical cases to illustrate the relevance of RAS mutations identified in ctDNA samples of patients with wild-type metastatic colorectal cancer who received an EGFR inhibitor plus chemotherapy as first-line treatment. The identification of RAS mutations in these patients is one of the most frequently identified mechanisms of acquired resistance. However, detecting a KRAS mutation via liquid biopsy can be caused by inter-tumor heterogeneity or it can be a false positive due to clonal hematopoiesis. More research is needed to determine whether ctDNA monitoring may help guide therapy options in metastatic colorectal cancer patients. We performed a literature review to assess the technologies that are used for analysis of RAS mutations on ctDNA, the degree of agreement between tissue and plasma and the importance of tissue/plasma discordant cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Low-frequency subclonal RAS mutations, which can be missed by conventional sequencing, can also lead to intrinsic resistance, necessitating the need for highly sensitive methods like next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis to detect mutations and guide treatment strategies [14].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 2×
“In this patient population, RAS/BRAF-acquired mutations were detected at the time of disease progression [15–17].”
BackgroundCervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“Besides primary resistance mechanisms, the efficacy of anti-EGFR agents in mCRC is limited by the development of molecular alterations producing acquired resistance [7,16,48,49].”
BackgroundClonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082
Integrating genomic features for non-invasive early lung cancer detection
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2140-0 · Cited by 685
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 678
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Hu, Y., Ulrich, B. C., Supplee, J., Kuang, Y., Lizotte, P. H., Feeney, N. B., Guibert, N. M., Awad, M. M., Wong, K.-K., Jänne, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0143 · Cited by 457
Cited by
Vdokaki, M.-E., Christopoulou, N.-M., Tsikas, P. K., & Christopoulos, T. K. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117837 · Cited by 3
Hisamatsu, Y., Ando, K., Kudo, K., Nakanishi, R., Kawazoe, T., Zaitsu, Y., Kusumoto, T., Hata, T., Kagawa, Y., Yoshizumi, T., et al. (2025) · Cancer Science · doi:10.1111/cas.70114 · Cited by 2
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“…RAS mutations, which can be missed by conventional sequencing, can also lead to intrinsic resistance, necessitating the need for highly sensitive methods like next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis to detect mutations and guide treatment strategies [14].”
Liquid Biopsies and Circulating Tumor DNA
Martínez‐Useros, J. (2026) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-032-24071-2_11
Guo, L., Song, J., Zang, H., Cao, Y., Lin, Y., Zheng, Z., Chen, S., Wen, L., Miao, Y., & Gu, W. (2026) · Hematological Oncology · doi:10.1002/hon.70218
Metadata
- Authors
- Popescu, I., Croitoru, V. M., Croitoru-Cazacu, I. M., Dudau, A.-M., Herlea, V., Dima, S. O., & Croitoru, A. E.
- Affiliations
- Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania
- Titu Maiorescu University (RO)
- Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Carol Davila University of Medicine and Pharmacy (RO)
- Institutul Clinic Fundeni (RO)
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2024-07-15
- Volume
- 14
- Issue
- 7
- Pages
- 750
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC11278408
- OpenAlex
- W4400668183
- Cited by
- 4
- References
- 61
- Citations by year
- 2026: 2 · 2025: 2
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- RAS mutations, circulating tumor DNA, liquid biopsy, metastatic colorectal cancer, EGFR inhibitors, acquired drug resistance, intertumoral heterogeneity, clonal hematopoiesis, first-line therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review. https://app.cochat.ai/papers/10.3390/jpm14070750
- The paper
- Popescu, I., Croitoru, V. M., Croitoru-Cazacu, I. M., Dudau, A.-M., Herlea, V., Dima, S. O., & Croitoru, A. E. (2024). Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review. Journal of Personalized Medicine. https://doi.org/10.3390/jpm14070750
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
